Medlab Clinical receives preliminary results from NanoStat™ trial

Medlab Clinical Ltd (ASX:MDC) has received and analysed the results of the NanoStat™ trial from Zenith in New Zealand. 

NanoStat is an investigative new sub-micron spray delivering a dosage of Atorvastatin in four pumps applied to the oro-buccal membrane (skin inside the mouth).

Atorvastatin is a statin medication used to lower cholesterol and was selected as it had specific comparative benefits when being tested in Medlab’s drug delivery platform (mouth spray).

Atorvastatin is predominantly provided to patients in tablet form.

Medlab aims to deliver medicinal cannabis using this drug delivery platform.

READ: Medlab outlines business development objectives at open day

Medlab’s CEO Dr Sean Hall said: “For those who recall why we undertook NanoCelle™ work with Atorvastatin, Atorvastatin had inherent properties that would test the NanoCelle™ capabilities beyond most generic drugs and our cannabis programs.

“These results further show the potential and widespread capabilities of the NanoCelle™ delivery platform.”

Post-results work shows benefits of spray over tablet ingestion

In work undertaken at our main laboratory in Alexandria post results, Medlab has improved NanoStat™ with data now indicating a 2 + times better blood level of free atorvastatin compared to the oral ingested Atorvastatin tablet.

Further, the work demonstrated that peak blood concentrations of free Atorvastatin was achieved in about 30 minutes, as previously compared to 53 minutes on the oral tablet.

Medlab considers the data extremely interesting as it has highlighted several areas of improvement which had previously not been obvious.

Moving forward Medlab intends to perfect this technique, develop the product further and look for potential new patents for Atorvastatin in light of the program findings to date.

Story by ProactiveInvestors